OliX PharmaceuticalsInc - Asset Resilience Ratio

Latest as of December 2025: 64.57%

OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 64.57% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check OliX PharmaceuticalsInc strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩126.15 Billion
≈ $85.49 Million USD Cash + Short-term Investments

Total Assets

₩195.37 Billion
≈ $132.40 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. See OliX PharmaceuticalsInc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OliX PharmaceuticalsInc (226950) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩126.15 Billion 64.57%
Total Liquid Assets ₩126.15 Billion 64.57%

Asset Resilience Insights

  • Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 64.57% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio

Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 5.66%
Royalty Pharma Plc
NASDAQ:RPRX
Biotechnology 0.11%
Abivax SA
PA:ABVX
Biotechnology 2.34%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 0.72%
Chongqing Zhifei Bio Products
SHE:300122
Biotechnology -0.08%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Theravance Biopharma Inc
F:0TB
Biotechnology 37.29%

Annual Asset Resilience Ratio for OliX PharmaceuticalsInc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 64.57% ₩126.15 Billion
≈ $85.49 Million
₩195.37 Billion
≈ $132.40 Million
+52.61pp
2024-12-31 11.96% ₩8.52 Billion
≈ $5.78 Million
₩71.25 Billion
≈ $48.28 Million
-1.59pp
2023-12-31 13.55% ₩13.93 Billion
≈ $9.44 Million
₩102.83 Billion
≈ $69.68 Million
-33.09pp
2022-12-31 46.64% ₩61.87 Billion
≈ $41.93 Million
₩132.65 Billion
≈ $89.90 Million
-10.77pp
2021-12-31 57.41% ₩49.76 Billion
≈ $33.72 Million
₩86.67 Billion
≈ $58.74 Million
-29.27pp
2020-12-31 86.68% ₩68.11 Billion
≈ $46.16 Million
₩78.58 Billion
≈ $53.25 Million
+42.54pp
2019-12-31 44.14% ₩19.95 Billion
≈ $13.52 Million
₩45.21 Billion
≈ $30.64 Million
-7.65pp
2018-12-31 51.79% ₩28.81 Billion
≈ $19.53 Million
₩55.64 Billion
≈ $37.70 Million
-0.51pp
2017-12-31 52.30% ₩11.32 Billion
≈ $7.67 Million
₩21.64 Billion
≈ $14.67 Million
-10.30pp
2016-12-31 62.60% ₩9.48 Billion
≈ $6.43 Million
₩15.15 Billion
≈ $10.27 Million
--
pp = percentage points

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology
Market Cap
$1.65 Billion
₩2.43 Trillion KRW
Market Cap Rank
#7008 Global
#186 in Korea
Share Price
₩120800.00
Change (1 day)
+4.86%
52-Week Range
₩34800.00 - ₩207000.00
All Time High
₩207000.00
About

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more